Alfred Scheidegger - Profile and Investment Details

Investor Profile

Alfred Scheidegger is a Venture Capital, Founder, Private Equity Firm, Investor based in Switzerland with a diverse investment portfolio that includes companies such as Black Diamond Therapeutics, Blueprint Medicines, TRACON Pharmaceuticals, Kura Kura International Ltd., Jounce Therapeutics, GANYMED Pharmaceuticals AG, Peloton TherapeuticsWemedoo AG, Arvinas, ImVisioN Therapeutics Inc., Cullinan Oncology, Silverback Therapeutics, Nextech Invest, Cleave Biosciences, Inc., Sunesis Pharmaceuticals, MolecularMD, MOMA Therapeutics, Scorpion Therapeutics, PMV Pharmaceuticals, ETH Zurich, Cleave Therapeutics, Rising Tide Foundation Group, Vividion Therapeutics, Turning Point Therapeutics, BioNeex UG, ImaginAb, BioVision AG, Neon Therapeutics, Telormedix, Ganymed Pharmaceuticals, Circle Pharma, Agensys, Inc., The Genetics Company, Palyon Medical Corporation, EQRx, Kronos Bio, A2 Biotherapeutics, Lipovectra Inc., TetraLogic Pharmaceuticals, MacroGenics, Inc., Kinnate Biopharma, Arrakis Therapeutics, Revolution Medicines, Kura Oncology, IconOVir Bio, IDEAYA Biosciences, Autolus, C4 Therapeutics, Agensys, . Over time, Alfred Scheidegger has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether Alfred Scheidegger is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Health Care, Women Founded, Life Science, Information Technology (IT), Biotechnology, Research, Digital Health, Travel, Medical, Therapeutics, Pharmaceuticals may find it worthwhile to explore potential connections with Alfred Scheidegger, as their portfolio suggests a familiarity and interest in this area.

Understanding Alfred Scheidegger’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.